129 related articles for article (PubMed ID: 2563374)
1. Disruption of the 290-342 salt bridge is not responsible for the secretory defect of the PiZ alpha 1-antitrypsin variant.
Sifers RN; Hardick CP; Woo SL
J Biol Chem; 1989 Feb; 264(5):2997-3001. PubMed ID: 2563374
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the Lys-290--Glu-342 salt bridge in human alpha 1-antitrypsin does not prevent its synthesis and secretion.
Foreman RC
FEBS Lett; 1987 May; 216(1):79-82. PubMed ID: 2884131
[TBL] [Abstract][Full Text] [Related]
3. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation.
Brantly M; Courtney M; Crystal RG
Science; 1988 Dec; 242(4886):1700-2. PubMed ID: 2904702
[TBL] [Abstract][Full Text] [Related]
4. Intracellular degradation of the transport-impaired human PiZ alpha 1-antitrypsin variant. Biochemical mapping of the degradative event among compartments of the secretory pathway.
Le A; Graham KS; Sifers RN
J Biol Chem; 1990 Aug; 265(23):14001-7. PubMed ID: 2380201
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.
Carlson JA; Rogers BB; Sifers RN; Finegold MJ; Clift SM; DeMayo FJ; Bullock DW; Woo SL
J Clin Invest; 1989 Apr; 83(4):1183-90. PubMed ID: 2784798
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342.
McCracken AA; Kruse KB; Brown JL
Mol Cell Biol; 1989 Apr; 9(4):1406-14. PubMed ID: 2786139
[TBL] [Abstract][Full Text] [Related]
7. Expression of PiM-and PiZ-mutated forms of the human alpha 1-antitrypsin gene in transfected monkey COS1 cells.
Davis ES; Harpaz N; Johnson EM
J Biol Chem; 1990 Dec; 265(36):22153-8. PubMed ID: 2266118
[TBL] [Abstract][Full Text] [Related]
8. Intracellular retention and degradation of human mutant variant of a alpha 1-antitrypsin in stably transfected Chinese hamster ovary cell lines.
Ciccarelli E; Alonso MA; Cresteil D; Bollen A; Jacobs P; Alvarez F
Eur J Biochem; 1993 Apr; 213(1):271-6. PubMed ID: 8477700
[TBL] [Abstract][Full Text] [Related]
9. Correcting the PiZ defect in the alpha 1-antitrypsin gene of human cells by targeted homologous recombination.
Savransky E; Hytiroglou P; Harpaz N; Thung SN; Johnson EM
Lab Invest; 1994 May; 70(5):676-83. PubMed ID: 8196364
[TBL] [Abstract][Full Text] [Related]
10. BiP expression is not increased by the accumulation of PiZ alpha 1-antitrypsin in the endoplasmic reticulum.
Cresteil D; Ciccarelli E; Soni T; Alonso MA; Jacobs P; Bollen A; Alvarez F
FEBS Lett; 1990 Jul; 267(2):277-80. PubMed ID: 2379586
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody specific for the mutant PiZ alpha 1-antitrypsin and its application in an ELISA procedure for identification of PiZ gene carriers.
Wallmark A; Alm R; Eriksson S
Proc Natl Acad Sci U S A; 1984 Sep; 81(18):5690-3. PubMed ID: 6207528
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of the insoluble PiZ variant of human alpha 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP.
Graham KS; Le A; Sifers RN
J Biol Chem; 1990 Nov; 265(33):20463-8. PubMed ID: 2122976
[TBL] [Abstract][Full Text] [Related]
13. Alpha 1-antitrypsin deficiency--a defect in secretion.
Foreman RC
Biosci Rep; 1987 Apr; 7(4):307-11. PubMed ID: 3499938
[TBL] [Abstract][Full Text] [Related]
14. Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion.
Curiel DT; Chytil A; Courtney M; Crystal RG
J Biol Chem; 1989 Jun; 264(18):10477-86. PubMed ID: 2567291
[TBL] [Abstract][Full Text] [Related]
15. A frameshift mutation results in a truncated alpha 1-antitrypsin that is retained within the rough endoplasmic reticulum.
Sifers RN; Brashears-Macatee S; Kidd VJ; Muensch H; Woo SL
J Biol Chem; 1988 May; 263(15):7330-5. PubMed ID: 3259232
[TBL] [Abstract][Full Text] [Related]
16. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
17. Soluble aggregates of the human PiZ alpha 1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis.
Le A; Ferrell GA; Dishon DS; Le QQ; Sifers RN
J Biol Chem; 1992 Jan; 267(2):1072-80. PubMed ID: 1530934
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of alpha 1-antitrypsin deficiency and its potential therapy by gene transfer.
Ledley FD; Woo SL
J Inherit Metab Dis; 1986; 9 Suppl 1():85-91. PubMed ID: 3097419
[TBL] [Abstract][Full Text] [Related]
19. Construction and expression of alpha 1-proteinase inhibitor mutants and the effects of these mutations on secretion of the variant inhibitors.
McCracken AA; Kruse KB; Valentine J; Roberts C; Yohannes TZ; Brown JL
J Biol Chem; 1991 Apr; 266(12):7578-82. PubMed ID: 2019587
[TBL] [Abstract][Full Text] [Related]
20. Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ.
Jeppsson JO
FEBS Lett; 1976 Jun; 65(2):195-7. PubMed ID: 1084290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
